Bestyrelsens beslutning om udstedelse af konvertible lån
February 07, 2024 03:46 ET
|
Pharma Equity Group A/S
Bestyrelsens beslutning om udstedelse af konvertible lån 7. februar 2024Meddelelse nr. 04 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af yderligere konvertible lån i...
The Board of Director's decision to issue convertible loans
February 07, 2024 03:46 ET
|
Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans 7 February 2024Company Announcement no. 04 The Board of Directors of Pharma Equity Group has decided on the issuance of additional...
Tegning af konvertible lån fuldført
January 25, 2024 04:08 ET
|
Pharma Equity Group A/S
25. januar 2024 Selskabsmeddelelse nr. 03 Tegning af konvertible lån fuldført Bestyrelsen i Pharma Equity Group besluttede den 22. januar 2024 at udstede konvertible lån i...
Completion of subscription of convertible loans
January 25, 2024 04:08 ET
|
Pharma Equity Group A/S
25 January 2024 Company Announcement No. 03 Completion of subscription of convertible loans On 22 January 2024 the Board of Directors in Pharma Equity Group decided to issue convertible...
Meddelelse fra European Patent Office (EPO) om udstedelse af patent på lægemiddelkompositioner til eliminering af bakterielle promotorer af kolorektal cancer ved intraluminal påføring (RNX-051).
January 22, 2024 10:15 ET
|
Pharma Equity Group A/S
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra European Patent Office (EPO) om udstedelse af patent på lægemiddelkompositioner til eliminering af...
Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).
January 22, 2024 10:15 ET
|
Pharma Equity Group A/S
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming...
Bestyrelsens beslutning om udstedelse af konvertible lån
January 22, 2024 09:54 ET
|
Pharma Equity Group A/S
Bestyrelsens beslutning om udstedelse af konvertible lån 22. januar 2024Meddelelse nr. 01 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold til...
The Board of Director's decision to issue convertible loans
January 22, 2024 09:54 ET
|
Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans 22 January 2024Company Announcement no. 01 The Board of Directors in Phama Equity Group has decided to issue convertible loans in...
Status for Selskabets tilgodehavende hos Portinho S.A.
November 28, 2023 12:30 ET
|
Pharma Equity Group A/S
28. november 2023 Meddelelse nr. 46 Status for Selskabets tilgodehavende hos Portinho S.A. Selskabets bestyrelse, valgt ind i forbindelse med at Selskabet blev omdannet til en...
Status of the Company's receivable from Portinho S.A.
November 28, 2023 12:30 ET
|
Pharma Equity Group A/S
November 28, 2023 Company Announcement no. 46 Status of the company's receivable from Portinho S.A. The Company's Board of Directors, which was elected in connection with the...